<DOC>
	<DOCNO>NCT02396862</DOCNO>
	<brief_summary>The purpose study improve understand key patient report outcome quality life well clinical outcome hemophilia A , global real world setting .</brief_summary>
	<brief_title>Patient Functioning Well-being , Economic , Clinical Impact Hemophilia A Its Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age 16 . Have documentation physicianconfirmed diagnosis moderate severe Hemophilia A ( severity define moderate = FVIII activity 1 % 5 % severe = FVIII activity â‰¤1 % ) . Signed write informed consent provide patient patient 's parent patient age 18 ( dependent local regulation ) . Signed write assent also require patient age 18 year ( dependent local regulation ) . Plan receive least half Hemophilia care registry site . Willing able enter data per data collection schedule . Currently receive prophylactic demand treatment ( include within last 6months demand ) . Expected life expectancy least 2 year . Patients Hemophilia B Patients von Willebrand disease ( vWD ) Patients rare bleed disorder Unable comply study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>